This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


BioComo Inc.
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2013/9/17
Profile

Delegates :
Masayuki Fukumura


Incorporated :
May   30 , 2008

Paid in Capital :
27 Million yen  

Employees :
2 人

Address :
Mie-gun, Komono-cho, Komono, 1325 MIE
〒5101233

TEL/FAX :
+81-59-392-7333 / +81-59-392-7333

URL:
http://www.biocomo.jp/?page_id=276

Attachment :

Mission/Background :
BioComo Inc. focuses on the research & development of a novel vaccine technology named 5’-PPP-RIV that prevents pathogenic infections and malignant tumors using respiratory infections human parainfluenza type 2 vector (hPIV2) developed in a Mie University graduate school medicine.

Technology & Business
  What is 5’-PPP-RIV technology?
5'-PPP-RIV is an unprecedented system for delivering antigens that can efficiently promote Th-1 immune response without adjuvants while inactivated paramyxovirus vector.
  Strong point of 5’-PPP-RIV
5’-PPP-RIV is a virus-like vesicle based on hPIV2 that can be processed by professional APCs and promote Th-1 biased immune response in a highly effective and efficient way.
As it can incorporate plural peptide antigens and efficiently induce a protective immune response without adjuvants, 5’-PPP-RIV is a flexible new tool for developing novel prophylactic and therapeutic vaccines for a variety of diseases.
  Business
・Providing of vaccine platform technology containing peptide antigens
・Development of prophylactic and therapeutic vaccines against infectious diseases and malignant tumors

Products & Service
Products & Service Name
Stage
Outline
Milestone
5’-PPP-RIV vaccine platforms
Discovery
a virus-like vesicle, named as 5’-PPP-IV, capable of incorporation of plural peptide antigens
a tie up, joint development
5’-PPP-RIV with a universal flu antigen, or infectious disease related antigens
Discovery
Prophylactic vaccine efficacy in animal testing
a tie up, joint development
5’-PPP-RIV with tumor associated antigens (TAAs)
Discovery
Inhibitory effect on growth of tumor cells in animal testing
a tie up, joint development








Highlights
We have applied for the patent and published the paper on the novel vaccine technology and started the establishment of the partnership with some companies to promote the development of vaccines. In addition, we have succeeded in the development of a high performance model of 5’-PPP-RIV that much more and more plural of antigen peptides can be introduced to.
Hot news

Alliance strategy
We hoped to work together or tie up with a pharmaceutical company or a biotech that is interested in novel vaccine technology in the areas of infectious diseases or malignant tumors.

 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.